Overview

Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Rigel Pharmaceuticals,Inc.
Treatments:
Decitabine
decitabine and cedazuridine drug combination
olutasidenib
venetoclax